Haemonetics’s Fiscal Q1 Earnings Surpass Analyst Estimates
Haemonetics reported an 8.7% YoY increase in revenues to $229.3 million during Q1 2019 as compared to revenues of $210.9 million during Q1 2018.
What Analysts Recommend for Haemonetics
Wall Street analysts estimate Haemonetics’s (HAE) Q1 2019 revenues to increase ~4.3% to $219.9 million as compared to $210.9 million during Q1 2018.
What Analysts Expect from Haemonetics in Q1 2019
Haemonetics is expected to report 4.3% growth in revenues to $219.9 million during Q1 2019 as compared to $210.9 million during Q1 2018.
Why HAE’s Blood Center Business Could See Small Revenue Decline
Haemonetics (HAE) expects its blood center business to report a year-over-year (or YoY) revenue decline in the range of 3% to 6% in fiscal 2019.
Commercial Launch of NexSys PCS May Boost Haemonetics’s Revenues
Haemonetics is also involved in plasma donor center experience programs that involve the use of NexSys PCS device and YES technology.
Plasma Business Continues to Be Key Growth Driver for Haemonetics
Haemonetics (HAE) expects its plasma franchise to report year-over-year (or YoY) revenue growth in the range of 7% to 10% in fiscal 2019.
Why Haemonetics Could Report Strong EPS Growth in Fiscal 2019
In fiscal 2019, Haemonetics (HAE) expects to report adjusted earnings per share (or EPS) in the range of $2.0 to $2.3.
Haemonetics Is Expected to Report Modest Revenue Growth in Fiscal 2019
In fiscal 2019, Haemonetics (HAE) expects to report year-over-year (or YoY) organic revenue growth in the range of 3% to 5% on a constant currency basis.
What Could Boost Haemonetics’ Revenues in Future Years
Haemonetics (HAE) expects its transfusion management business to grow at compound annual growth rate (or CAGR) in the low to mid teens.
HAE Focuses on Revitalizing Cell Salvage Business in Fiscal 2018
Haemonetics (HAE) is currently the number one or number two player in the cell salvage segment in most of the geographies in which the company competes.
The Hospital Business Remains 1of HAE’s Key Growth Drivers
In fiscal 3Q18, Haemonetics (HAE) reported revenue of close to $46.7 million in its hospital business, a YoY (year-over-year) rise of ~9.1%.
HAE Is Well Placed to Compete in Plasma Collection in Fiscal 2018
Haemonetics (HAE) is focused on initiating the commercial launch of its innovative NexSys PCS device coupled with its embedded firmware, NexLynk DMS, in 2H18.
Plasma Remains an Attractive Business for HAE
In fiscal 2017, Haemonetics (HAE) earned almost 46% of its total revenue from its plasma franchise.
Plasma Continues to Drive Strong Growth for HAE in Fiscal 2018
In fiscal 3Q18, Haemonetics (HAE) reported revenue of close to $113.1 million, a YoY (year-over-year) rise of ~4.1%.
HAE Expects a Modest Net Profit Margin Expansion in Fiscal 2018
On its fiscal 3Q18 earnings conference call, Haemonetics increased the guidance for its fiscal 2018 adjusted EPS to the range $1.80–$1.90.
HAE Is Expected to Report Flat Revenue Performance in Fiscal 2018
Haemonetics (HAE) expects to report fiscal 2018 revenue in line with what it witnessed in fiscal 2017.
Analysts’ Recommendations for Haemonetics and Peers in March 2018
In its fiscal 3Q18, which ended on December 31, 2017, Haemonetics (HAE) reported revenue of close to $234 million.